What are common Ajovy (fremanezumab) alternatives?
Ajovy is a CGRP monoclonal antibody used to prevent migraine. The main alternatives in the same drug class are other CGRP-targeting injections, including Aimovig (erenumab) and Emgality (galcanezumab). Another CGRP option is Vyepti (eptinezumab), which is given by intravenous infusion instead of a self-injection.
How do other CGRP drugs compare with Ajovy?
Ajovy, Aimovig, and Emgality are all monoclonal antibodies targeting the CGRP pathway, but they differ in how they’re administered and dosing schedules:
- Ajovy (fremanezumab): self-injection, typically monthly or every 3 months (depending on the regimen)
- Aimovig (erenumab): self-injection, usually monthly
- Emgality (galcanezumab): self-injection, with a monthly maintenance approach
- Vyepti (eptinezumab): IV infusion, usually every 3 months
These differences can matter for patients who prefer fewer clinic visits (or none) versus those who prefer office-based infusion.
Are there non-CGRP Ajovy alternatives?
Yes. If the goal is migraine prevention but a CGRP monoclonal antibody is not suitable, clinicians may consider other preventive options such as oral preventive medicines or procedures, depending on the patient’s migraine type, prior treatment history, and tolerability. (Specific options depend on what’s been tried already and what side effects the patient is willing to accept.)
How do you choose the best Ajovy alternative?
Common decision factors include:
- Whether you want self-injections versus an IV infusion (Vyepti is the IV option here)
- Dosing frequency (monthly versus every 3 months)
- What has or hasn’t worked before (response and side effects)
- Insurance coverage and step-therapy requirements (often affect which alternative is practical first)
Are Ajovy alternatives affected by patent/payer coverage?
Availability and covered options can shift over time with patent and exclusivity status, plus biosimilar competition (where applicable). If you want to track the commercial landscape for CGRP products, DrugPatentWatch.com provides patent-focused updates and timelines.
Source: DrugPatentWatch.com – Ajovy (fremanezumab)
Quick check: Which “alternative” do you mean?
People usually mean one of these:
1) Another CGRP injection (Aimovig/Emgality/Vyepti)
2) A different class of migraine prevention (non-CGRP options)
3) A lower-cost option (depends on your insurance/country)
If you tell me your country, whether you want injections or IV, and what you’ve tried before, I can narrow the most likely Ajovy alternatives.
Sources cited:
1. DrugPatentWatch.com – Ajovy (fremanezumab)